Table 2. Association of BRAF mutational status with clinicopathological parameters stratified according to tumor thickness.

	Tumor thickness ≤1 mm (n = 239)				Tumor thickness >1 mm (n = 198)
Characteristic	Rate Mutant	Mutant	Wild type	p-valuea	Rate Mutant	Mutant	Wild type	p-valuea
All patients	34.7%	83	156		43.4%	86	112
Gender				0.419				0.253
Male	32.2%	39	82		47.2%	51	57
Female	37.3%	44	74		38.9%	35	55
Age				<0.001				0.034
<50 years	50.0%	43	43		60.0%	27	18
50–59 years	37.9%	22	36		40.8%	20	29
60–69 years	27.6%	16	42		43.9%	25	32
≥70 years	5.4%	2	35		29.8%	14	33
Ulceration				0.545				0.605
Yes	0.0%	0	2		47.7%	21	23
No	35.0%	83	154		42.2%	65	89
Tumor thickness				0.143				1.000
≤0.50 mm	30.2%	29	67
0.51–0.75 mm	33.0%	30	61
0.76–1.00 mm	46.2%	24	28
1.01–2.00 mm					43.8%	60	77
2.01–4.00 mm					42.2%	19	26
>4.00 mm					43.8%	7	9
Histological subtype				<0.001				0.001
SSM	39.7%	81	123		48.4%	60	64
NM		0	0		57.7%	15	11
LMM	3.3%	1	29		9.1%	2	20
ALM	20.0%	1	4		32.0%	8	17
Clark level				0.135				0.159
I–III	32.7%	66	136		53.7%	22	19
IV or V	45.9%	17	20		40.8%	64	94
Mitoses/mm2				1.000				0.046
<1	34.1%	57	110		30.0%	15	35
≥1	34.3%	24	46		47.3%	69	77

^ap-values are results of Chi-square tests.